Adicet Bio, Inc. Restructuring and Related Cost, Incurred Cost
Adicet Bio, Inc. (ACET) reported Restructuring and Related Cost, Incurred Cost of $800.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2022-11-08
- 2022-09-30: Restructuring and Related Cost, Incurred Cost 9 month $800.00K.
| Period end | Restructuring and Related Cost, Incurred Cost 9 month |
|---|---|
| 2022-09-30 | $800.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |